Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid antibodies: specificity and pathophysiology

P G de Groot1, J D Oosting, R H Derksen

  • 1University Hospital Utrecht, Department of Haematology, The Netherlands.

Bailliere'S Clinical Haematology
|September 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Haemostatic changes in urogenital schistosomiasis haematobium: a case-control study in Gabonese schoolchildren.

Journal of helminthology·2019
Same author

For Debate: Personalized Health Care: As Exemplified by Home Sodium Measurements in a Child with Central Diabetes Insipidus and Impaired Thirst Perception.

Pediatric endocrinology reviews : PER·2018
Same author

High prevalence of reduced thrombin generation and/or decreased platelet response in women with unexplained heavy menstrual bleeding.

International journal of laboratory hematology·2018
Same author

Decreased plasma levels of activated factor VII in patients with deep vein thrombosis.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Increased factor XIa levels in patients with a first acute myocardial infarction: the introduction of a new thrombin generation based factor XIa assay.

Thrombosis research·2014
Same author

Cirrhosis patients have a coagulopathy that is associated with decreased clot formation capacity.

Journal of thrombosis and haemostasis : JTH·2014
Same journal

Current status of stem cell therapy and prospects for gene therapy for the disorders of globin synthesis.

Bailliere's clinical haematology·2000
Same journal

Pharmacological therapy.

Bailliere's clinical haematology·2000
Same journal

Prenatal diagnosis and screening of the haemoglobinopathies.

Bailliere's clinical haematology·2000
Same journal

Sickle cell disease: clinical management.

Bailliere's clinical haematology·2000
Same journal

Pathophysiology of sickle cell disease.

Bailliere's clinical haematology·2000
Same journal

Thalassaemia: clinical management.

Bailliere's clinical haematology·2000
See all related articles

Antiphospholipid antibodies are a diverse group of autoantibodies targeting phospholipid-protein complexes. Their pathological capacity depends on inhibiting the protein cofactor

Area of Science:

  • Immunology
  • Hematology
  • Autoimmunity

Background:

  • Antiphospholipid antibodies (aPL) are associated with thrombosis and pregnancy loss.
  • The precise antigen and pathogenic mechanism of aPL remain incompletely understood.
  • Current understanding suggests aPL target phospholipid-protein complexes rather than phospholipids alone.

Purpose of the Study:

  • To investigate the heterogeneity of antiphospholipid antibodies.
  • To identify novel protein cofactors involved in aPL antigenicity.
  • To elucidate the pathogenic mechanisms underlying aPL-associated thrombosis.

Main Methods:

  • ELISA assays for aPL detection.
  • Coagulation assays to assess clotting time.
  • Investigation of various protein cofactors (beta 2-glycoprotein I, prothrombin, protein C, protein S).

Related Experiment Videos

Main Results:

  • Antiphospholipid antibodies are heterogeneous, targeting various phospholipid-protein complexes.
  • Beta 2-glycoprotein I and prothrombin act as cofactors in aPL detection.
  • Physiologically relevant cofactors like protein C and S also bind aPL, suggesting diverse pathogenic roles.

Conclusions:

  • Antiphospholipid antibodies represent a heterogeneous group with varying affinities for different protein-phospholipid complexes.
  • The pathogenic capacity of aPL is determined by their ability to inhibit the biological activity of the protein component within these complexes.
  • Further research into these complexes is crucial for understanding and managing aPL-associated conditions.